Targeting Wnt2b in TAMs might be a great potential treatment strategy in immune therapy of HCC, and TLR9 agonist CpG ODN might act as a Wnt2b signal inhibitor for HCC therapy. This evidence concerns the gene WNT2B and hepatocellular carcinoma.